Hainan Lingkang Pharmaceutical Co., Ltd.

Flumazenil is a benzodiazepine receptor antagonist that competitively inhibits the reaction of benzodiazepines with their receptors, thereby specifically blocking their central nervous system effects.

Benzodiazepine receptor antagonists, which competitively inhibit the reaction of benzodiazepines with their receptors, thereby specifically blocking their central nervous system effects.

None

Benzodiazepine receptor antagonists, which competitively inhibit the reaction of benzodiazepines with their receptors, thereby specifically blocking their central nervous system effects.

Cefepime is a broad-spectrum fourth-generation cephalosporin that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. In vitro tests have shown that this product is effective against both Gram-positive and Gram-negative bacteria. This product has low affinity for beta-lactamase encoded by bacterial chromosomes, can highly tolerate the hydrolysis of most beta-lactamases, and can quickly penetrate into the cells of Gram-negative bacteria. In bacterial cells, its target molecule is penicillin-binding protein (PBP). In vitro and clinical studies have confirmed that this product is active against most of the following microorganisms: Gram-negative aerobic microorganisms: Enterobacter, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa; Gram-positive aerobic microorganisms: Staphylococcus aureus (only for methicillin-sensitive strains), Streptococcus pyogenes (Group A streptococci), Streptococcus pneumoniae; in addition, this product also has antibacterial activity against some other Gram-negative aerobic microorganisms (such as Acinetobacter calcoaceticus, Citrobacter freundii, etc.) and anaerobic microorganisms.